SINT
BEARISH
$2.69
Live
Sintx Technologies, Inc. · NASDAQ
Target $10.17
(+277.9%)
$1.72
52W Range
$6.78
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$11.09M
P/E
N/A
ROE
-303.8%
Profit margin
N/A
Debt/Equity
1.11
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
SINT exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -787.59%. The company is experiencing a collapse in its top line with YoY revenue growth at -46.50% and a consistent track record of missing earnings estimates (0/4 beats in the last year). Despite a 'Strong Buy' analyst consensus and a target price of $10.17, the fundamental data suggests a company in a death spiral with a 5-year price change of -100%. The disconnect between analyst optimism and the deterministic health scores indicates extreme speculative risk.
Key Strengths
Positive Gross Margin (45.28%) suggesting some product-level viability
Current Ratio of 1.51 provides a minimal short-term liquidity buffer
Quick Ratio of 1.16 indicates ability to cover immediate liabilities
Recent 1-year price recovery (+53.7%) shows speculative interest
Low Debt/Equity (1.11) relative to some healthcare peers
Key Risks
Severe revenue contraction (-46.50% YoY)
Extreme operational inefficiency (Operating Margin -787.59%)
Massive equity erosion (ROE -303.80%)
Consistent and significant earnings misses (Avg Surprise -195.66%)
Micro-cap volatility and high risk of bankruptcy given the F-Score
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
6
Weak
10
5
0
15
0
AI Verdict
Critical Failure
Key drivers: Piotroski F-Score 1/9, Negative Revenue Growth, Catastrophic Operating Margins, Total 5-Year Value Destruction
Confidence
90%
Value
10/100
P/S and P/B are decoupled from fundamental performance.
Positives
No standout positives identified.
Watchpoints
- Price/Sales of 10.89 is unjustifiable for a shrinking company
- Price/Book of 3.64 is high for a distressed asset
- No Graham Number available due to lack of earnings
Future
5/100
Growth metrics are trending aggressively downward.
Positives
No standout positives identified.
Watchpoints
- Revenue growth is sharply negative (-46.50%)
- EPS growth is plummeting (-229.5% Q/Q)
- Zero earnings beats in the last 4 quarters
Past
0/100
Historical performance indicates total loss of shareholder value.
Positives
No standout positives identified.
Watchpoints
- 5-Year price change of -100%
- 3-Year price change of -99.3%
- Long history of massive EPS misses
Health
15/100
F-Score is the primary deterministic indicator of distress.
Positives
- Current ratio > 1.0
Watchpoints
- Piotroski F-Score 1/9 indicates extreme weakness
- ROE of -303.80% shows rapid capital depletion
Dividend
0/100
Dividend strength is 0/100.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No capacity to pay dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.69
Analyst Target
$10.17
Upside/Downside
+277.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SINT and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SINT
Sintx Technologies, Inc.
Primary
|
-100.0% | -99.3% | +53.7% | -32.1% | +1.1% | +0.4% |
|
NCEL
NewcelX Ltd.
Peer
|
-99.8% | -99.6% | -82.6% | -85.8% | -5.6% | +21.1% |
|
NXL
Nexalin Technology, Inc.
Peer
|
-77.4% | -35.6% | -70.6% | -64.9% | +25.1% | +45.4% |
|
BNGO
Bionano Genomics, Inc.
Peer
|
-100.0% | -99.8% | -64.6% | -35.8% | +0.9% | +3.6% |
|
GDTC
CytoMed Therapeutics Limited
Peer
|
-75.0% | -75.0% | -63.5% | -55.6% | -5.7% | +1.2% |
SIN
Sintx Technologies, Inc.
Primary
5Y
-100.0%
3Y
-99.3%
1Y
+53.7%
6M
-32.1%
1M
+1.1%
1W
+0.4%
NCE
NewcelX Ltd.
Peer
5Y
-99.8%
3Y
-99.6%
1Y
-82.6%
6M
-85.8%
1M
-5.6%
1W
+21.1%
NXL
Nexalin Technology, Inc.
Peer
5Y
-77.4%
3Y
-35.6%
1Y
-70.6%
6M
-64.9%
1M
+25.1%
1W
+45.4%
BNG
Bionano Genomics, Inc.
Peer
5Y
-100.0%
3Y
-99.8%
1Y
-64.6%
6M
-35.8%
1M
+0.9%
1W
+3.6%
GDT
CytoMed Therapeutics Limited
Peer
5Y
-75.0%
3Y
-75.0%
1Y
-63.5%
6M
-55.6%
1M
-5.7%
1W
+1.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.53
PEG Ratio
N/A
P/B Ratio
3.64
P/S Ratio
10.89
EV/Revenue
10.02
EV/EBITDA
-1.0
Market Cap
$11.09M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-787.59%
Gross Margin
45.28%
ROE
-303.8%
ROA
-69.8%
Growth
Revenue and earnings growth rates
Revenue Growth
-46.5%
Earnings Growth
N/A
Q/Q Revenue Growth
-2.08%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.11
Moderate
Current Ratio
1.51
Good
Quick Ratio
1.16
Good
Cash/Share
$1.0
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
45.7%
Op. Margin
-1233.0%
Net Margin
-1178.2%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
2.25x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
102%
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-12
$-3.46
-529.1% surprise
2025-08-14
$-1.05
-33.3% surprise
2025-05-15
$-1.28
-80.1% surprise
2025-03-19
$-4.37
-140.1% surprise
Healthcare Sector Comparison
Comparing SINT against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-303.8%
This Stock
vs
-97.42%
Sector Avg
+211.9%
(Excellent)
Debt to Equity
1.11
This Stock
vs
3.06
Sector Avg
-63.7%
(Less Debt)
Revenue Growth
-46.5%
This Stock
vs
147.85%
Sector Avg
-131.5%
(Slower)
Current Ratio
1.51
This Stock
vs
4.68
Sector Avg
-67.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SINT
Sintx Technologies, Inc.
|
BEARISH | $11.09M | - | -303.8% | -% | $2.69 | |
|
NCEL
NewcelX Ltd.
|
BEARISH | $11.49M | - | -% | -% | $2.52 | Compare |
|
NXL
Nexalin Technology, Inc.
|
BEARISH | $10.48M | - | -221.5% | -% | $0.51 | Compare |
|
BNGO
Bionano Genomics, Inc.
|
BEARISH | $11.7M | - | -78.2% | -134.4% | $1.15 | Compare |
|
GDTC
CytoMed Therapeutics Limited
|
BEARISH | $11.83M | - | -50.3% | -% | $1.0 | Compare |
SINT
Sintx Technologies, Inc.
BEARISH
Mkt Cap
$11M
P/E
-
ROE
-303.8%
Price
$2.69
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-13 | ELMORE ROBERT RYAN | President | Stock Award | 4,910 | $14,165 |
| 2026-03-02 | LYONS CHRISTOPHER MICHAEL | Director | Purchase | 8,292 | $24,092 |
| 2026-02-23 | MOYES JAY M | Director | Purchase | 1,000 | $2,910 |
| 2026-02-18 | ANDERSON MARK LEWIS | Director | Purchase | 3,000 | $9,060 |
| 2025-12-08 | HONIGBLUM GREGG R. | Chief Investment Officer | Purchase | 8,200 | $34,896 |
| 2025-12-05 | HONIGBLUM GREGG R. | Chief Investment Officer | Stock Award | 53,867 | - |
| 2025-12-05 | HONIGBLUM GREGG R. | Chief Investment Officer | Purchase | 65,000 | $255,350 |
| 2025-11-07 | HONIGBLUM GREGG R. | Chief Investment Officer | Purchase | 10,000 | $31,900 |
ELMORE ROBERT RYAN
President
2026-04-13
4,910 shares
·
$14,165
LYONS CHRISTOPHER MICHAEL
Director
2026-03-02
8,292 shares
·
$24,092
MOYES JAY M
Director
2026-02-23
1,000 shares
·
$2,910
ANDERSON MARK LEWIS
Director
2026-02-18
3,000 shares
·
$9,060
HONIGBLUM GREGG R.
Chief Investment Officer
2025-12-08
8,200 shares
·
$34,896
HONIGBLUM GREGG R.
Chief Investment Officer
2025-12-05
53,867 shares
HONIGBLUM GREGG R.
Chief Investment Officer
2025-12-05
65,000 shares
·
$255,350
HONIGBLUM GREGG R.
Chief Investment Officer
2025-11-07
10,000 shares
·
$31,900
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-K
10-Q
8-K
10-Q
DEF 14A
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
3 analysts
HC Wainwright & Co.
2026-04-13
Buy
Ascendiant Capital
2026-04-08
Buy
Buy
Ascendiant Capital
2025-12-08
Buy
Buy
Past News Coverage
Recent headlines mentioning SINT from our newsroom.
Newest → oldest
No matching news yet.